{"schema_version":"secwatch.filing_event.v1","accession":"0001628908-23-000069","form_type":"8-K","ticker":"EVH","cik":"0001628908","company_name":"Evolent Health, Inc.","filed_at":"2023-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.734222+00:00","generated_at":"2026-06-14T17:20:36.178005+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Evolent Health targets $1.95B revenue, $190M adj. EBITDA for 2023 at Investor Day","bullets":["2023 revenue outlook midpoint $1.95B; adjusted EBITDA midpoint $190M.","Revenue CAGR of 39% from Q4 2019 to Q1 2023; Q1 2023 revenue $427.7M.","Cross-sell opportunity of $50B out of $150B specialty TAM; revenue renewal rate ~110% in 2022.","Performance Suite mature flow-through margins estimated at 12-18%; capital-light model emphasized.","TTM adjusted EBITDA $132.6M; TTM revenue (ex-divested) $1.35B."],"urls":{"canonical":"https://secwatch.observer/filing/0001628908-23-000069","json":"https://secwatch.observer/filing/0001628908-23-000069.json","markdown":"https://secwatch.observer/filing/0001628908-23-000069.md","text":"https://secwatch.observer/filing/0001628908-23-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000069/0001628908-23-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000069/evh-20230523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T17:20:36.178005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}